306 related articles for article (PubMed ID: 30353269)
21. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
22. Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients.
González-Fernández MÁ; Villamañán E; Jiménez-Nácher I; Moreno F; Herrero A; Balsa A
Farm Hosp; 2019 Jan; 43(1):24-30. PubMed ID: 30624170
[TBL] [Abstract][Full Text] [Related]
23. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
24. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
[TBL] [Abstract][Full Text] [Related]
26. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
27. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
Thomas K; Flouri I; Repa A; Fragiadaki K; Sfikakis PP; Koutsianas C; Kaltsonoudis E; Voulgari PV; Drosos AA; Petrikkou E; Sidiropoulos P; Vassilopoulos D
Clin Exp Rheumatol; 2018; 36(2):254-262. PubMed ID: 29148406
[TBL] [Abstract][Full Text] [Related]
28. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
[TBL] [Abstract][Full Text] [Related]
29. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
[TBL] [Abstract][Full Text] [Related]
30. Biologics, spondylitis and COVID-19.
Rosenbaum JT; Hamilton H; Choi D; Weisman MH; Reveille JD; Winthrop KL
Ann Rheum Dis; 2020 Dec; 79(12):1663-1665. PubMed ID: 32522741
[No Abstract] [Full Text] [Related]
31. Retention of golimumab treatment following discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry.
Pombo-Suárez M; Sanchez-Piedra C; Ruiz-Montesino D; Diaz-Torne C; Jovaní V; Cea-Calvo L; Castrejón I
Musculoskeletal Care; 2022 Jun; 20(2):403-407. PubMed ID: 34668303
[No Abstract] [Full Text] [Related]
32. Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors.
Tymms K; Littlejohn G; Griffiths H; de Jager J; Bird P; Joshua F; Nash P; Handel M; McManus H; Butcher BE; Youssef P
Clin Rheumatol; 2018 Jun; 37(6):1617-1623. PubMed ID: 29667098
[TBL] [Abstract][Full Text] [Related]
33. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry.
Prior-Español A; Sánchez-Piedra C; Campos J; Manero FJ; Pérez-García C; Bohórquez C; Busquets-Pérez N; Blanco-Madrigal JM; Díaz-Torne C; Sánchez-Alonso F; Mateo L; Holgado-Pérez S
Sci Rep; 2021 May; 11(1):11091. PubMed ID: 34045525
[TBL] [Abstract][Full Text] [Related]
34. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
[TBL] [Abstract][Full Text] [Related]
36. Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study.
Gehin JE; Warren DJ; Syversen SW; Lie E; Sexton J; Loli L; Wierød A; Bjøro T; Kvien TK; Bolstad N; Goll GL
Scand J Rheumatol; 2021 Nov; 50(6):445-454. PubMed ID: 33650469
[No Abstract] [Full Text] [Related]
37. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain.
Alonso A; González CM; Ballina J; García Vivar ML; Gómez-Reino JJ; Marenco JL; Fernández-Nebro A; Ordás C; Cea-Calvo L; Arteaga MJ; Sanmartí R
Reumatol Clin; 2015; 11(3):144-50. PubMed ID: 25022442
[TBL] [Abstract][Full Text] [Related]
38. Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model.
Krabbe S; Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Jarbøl DE; Østergaard M; Hetland ML
Rheumatology (Oxford); 2021 Aug; 60(8):3834-3844. PubMed ID: 33493342
[TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
